CWCasey Elizabeth Wing

Casey Elizabeth Wing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Casey Elizabeth Wing has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Yuh Min Chook

    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, USA

    5 shared publications
  • Ho Yee Joyce Fung

    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, USA

    4 shared publications
  • Ashley B. Niesman

    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, USA

    3 shared publications
  • Bert Kwanten

    KU Leuven Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute for Medical Research, Leuven Cancer Institute (LKI), Leuven, Belgium

    3 shared publications
  • Dirk Daelemans

    KU Leuven Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute, Leuven Cancer Institute, Herestraat 49, Leuven, 3000, Belgium

    3 shared publications
  • Maarten Jacquemyn

    KU Leuven Department of Microbiology, Immunology and Transplantation; Molecular Genetics and Therapeutics in Virology and Oncology Research Group; Rega Institute; Leuven Cancer Institute, Leuven, Belgium

    3 shared publications

Latest Publications

  • Open Access

    Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy

    by Janne Van Hauwenhuyse, Felien Reniers, Leentje Persoons, Sam Noppen, Casey E. Wing, Ashley B. Niesman, Ho Yee Joyce Fung, Els Vanstreels, Maarten Jacquemyn, Eline Boel, et al.

    Exportin 1 (XPO1/CRM1) is a clinically validated anticancer target whose inhibition blocks nuclear export and promotes cancer cell apoptosis. Current XPO1 inhibitors rely on covalent Michael addition to Cys528 in the nuclear export signal binding groove of XPO1. Here, we describe a novel XPO1 inhibitor, FR-027, that targets Cys528 through nucleophilic aromatic substitution. In contrast to clinical-stage XPO1 inhibitors selinexor and eltanexor, FR-027 acts reversibly and does not promote XPO1 protein degradation. Structural analysis of the XPO1-FR-027 complex reveals covalent modification of Cys528 and a closed-groove conformation that prevents degradation. FR-027 demonstrates potent on-target activity across multiple cancer cell types and delays disease progression while extending overall survival in xenograft and syngeneic models, including intracranial tumors. Notably, FR-027 does not induce significant thrombocytopenia, lymphopenia, or neutropenia in heavily treated mice. These findings underscore the distinct molecular and pharmacological properties of FR-027 and support its further evaluation for clinical development in diseases with significant unmet medical needs.


  • SINE compounds activate exportin 1 degradation through an allosteric mechanism

    by Casey E. Wing, Ho Yee Joyce Fung, Bert Kwanten, Tolga Cagatay, Ashley B. Niesman, Maarten Jacquemyn, Mehdi Gharghabi, Brecht Permentier, Binita Shakya, Rhituparna Nandi, et al.

    Overexpression of exportin 1 (XPO1/CRM1) in cancer cells mislocalizes numerous cancer-related nuclear export cargoes. Covalent selective inhibitors of nuclear export (SINEs), including the cancer drug selinexor, restore proper nuclear localization by blocking XPO1–cargo interaction. These inhibitors also induce XPO1 degradation through the Cullin–RING E3 ligase (CRL) substrate receptor ASB8. Here we present cryo-electron microscopy structures revealing ASB8 binding to a cryptic XPO1 site that is exposed upon SINE conjugation. Unlike typical molecular glue degraders that directly bridge CRLs and substrates, SINEs bind XPO1 independently of ASB8, triggering an allosteric mechanism that enables high-affinity ASB8 recruitment, leading to XPO1 ubiquitination and degradation. ASB8-mediated degradation is also triggered by the endogenous itaconate derivative 4-octyl itaconate, suggesting that synthetic XPO1 inhibitors exploit a native cellular mechanism. This allosteric XPO1 degradation mechanism expands known modes of targeted protein degradation beyond molecular glue degraders and proteolysis-targeting chimeras of CRL4.


  • Open Access

    SINE compounds activate exportin-1 degradation via an allosteric mechanism

    by Casey Elizabeth Wing, Ho Yee Joyce Fung, Bert Kwanten, Tolga Cagatay, Ashley B. Niesman, Maarten Jacquemyn, Mehdi Gharghabi, Brecht Permentier, Binita Shakya, Rhituparna Nandi, et al.

    The nuclear export receptor exportin 1 (XPO1/CRM1) is often overexpressed in cancer cells, leading to the mislocalization of numerous cancer-related protein cargoes 1,2 . Selinexor, a covalent XPO1 inhibitor, and other Selective Inhibitor of Nuclear Export (SINEs) restore proper nuclear localization by blocking XPO1-cargo binding 2-7 . SINEs also induce XPO1 degradation via the Cullin-RING E3 ubiquitin ligase (CRL) substrate receptor ASB8 7 . Here we elucidate the mechanism underlying the high-affinity engagement of CRL5 ASB8 with SINE-conjugated XPO1. Cryogenic electron microscopy (cryoEM) structures reveal that ASB8 binds to a cryptic site on XPO1, which becomes accessible only upon SINE conjugation. While molecular glue degraders typically interact with both CRL and the substrate 8-10 , SINEs bind to XPO1 without requiring interaction with ASB8 for efficient XPO1 degradation. Instead, an allosteric mechanism facilitates high affinity XPO1-ASB8 interaction, leading to XPO1 ubiquitination and degradation. ASB8-mediated degradation is also observed upon treatment of the endogenous itaconate derivate 4-octyl itaconate, which suggests a native mechanism that is inadvertently exploited by synthesized XPO1 inhibitors. This allosteric XPO1 degradation mechanism of SINE compounds expands the known modes of targeted protein degradation beyond the well-characterized molecular glue degraders and proteolysis targeting chimeras of CRL4.


  • Top Cited Papers

    Karyopherin-mediated nucleocytoplasmic transport

    by Casey E. Wing, Ho Yee Joyce Fung, Yuh Min Chook

    Efficient and regulated nucleocytoplasmic trafficking of macromolecules to the correct subcellular compartment is critical for proper functions of the eukaryotic cell. The majority of the macromolecular traffic across the nuclear pores is mediated by the Karyopherin-β (or Kap) family of nuclear transport receptors. Work over more than two decades has shed considerable light on how the different Kap family members bring their respective cargoes into the nucleus or the cytoplasm in efficient and highly regulated manners. In this Review, we overview the main features and established functions of Kap family members, describe how Kaps recognize their cargoes and discuss the different ways in which these Kap–cargo interactions can be regulated, highlighting new findings and open questions. We also describe current knowledge of the import and export of the components of three large gene expression machines — the core replisome, RNA polymerase II and the ribosome — pointing out the questions that persist about how such large macromolecular complexes are trafficked to serve their function in a designated subcellular location.


  • Open Access

    Exploring bioactive peptides from bacterial secretomes using Pep SAVI ‐ MS : identification and characterization of Bac‐21 from Enterococcus faecalis pPD 1

    by Christine L. Kirkpatrick, Nicole C. Parsley, Tessa E. Bartges, Casey E. Wing, Sushma Kommineni, Christopher J. Kristich, Nita H. Salzman, Steven M. Patrie, Leslie M. Hicks

    Summary: As current methods for antibiotic drug discovery are being outpaced by the rise of antimicrobial resistance, new methods and innovative technologies are necessary to replenish our dwindling arsenal of antimicrobial agents. To this end, we developed the Pep SAVI ‐ MS pipeline to expedite the search for natural product bioactive peptides. Herein we demonstrate expansion of Pep SAVI ‐ MS for the discovery of bacterial‐sourced bioactive peptides through identification of the bacteriocin Bac‐21 from Enterococcus faecalis pPD 1. Minor pipeline modifications including implementation of bacteria‐infused agar diffusion assays and optional digestion of peptide libraries highlight the versatility and wide adaptability of the Pep SAVI ‐ MS pipeline. Additionally, we have experimentally validated the primary protein sequence of the active, mature Bac‐21 peptide for the first time and have confirmed its identity with respect to primary sequence and post‐translational processing. Successful application of Pep SAVI ‐ MS to bacterial secretomes as demonstrated herein establishes proof‐of‐principle for use in novel microbial bioactive peptide discovery.


  • Continuous Elution Proteoform Identification of Myelin Basic Protein by Superficially Porous Reversed-Phase Liquid Chromatography and Fourier Transform Mass Spectrometry

    by Daniel A. Plymire, Casey E. Wing, Dana E. Robinson, Steven M. Patrie

    Myelin basic protein (MBP) plays an important structural and functional role in the neuronal myelin sheath. Translated MBP exhibits extreme microheterogeneity with numerous alternative splice variants (ASVs) and post-translational modifications (PTMs) reportedly tied to central nervous system maturation, myelin stability, and the pathobiology of various de- and dys-myelinating disorders. Conventional bioanalytical tools cannot efficiently examine ASV and PTM events simultaneously, which limits understanding of the role of MBP microheterogeneity in human physiology and disease. To address this need, we report on a top-down proteomics pipeline that combines superficially porous reversed-phase liquid chromatography (SPLC), Fourier transform mass spectrometry (FTMS), data-independent acquisition (DIA) with nozzle-skimmer dissociation (NSD), and aligned data processing resources to rapidly characterize abundant MBP proteoforms within murine tissue. The three-tier proteoform identification and characterization workflow resolved four known MBP ASVs and hundreds of differentially modified states from a single 90 min SPLC-FTMS run on ∼0.5 μg of material. This included 323 proteoforms for the 14.1 kDa ASV alone. We also identified two novel ASVs from an alternative transcriptional start site (ATSS) of the MBP gene as well as a never before characterized S-acylation event linking palmitic acid, oleic acid, and stearic acid at C78 of the 17.125 kDa ASV.